US EditionPublished • loading... • Updated
Kangpu to Present Latest Study Results of epaldeudomide (KPG-818) at the 67th ASH Annual Meeting
Summary by Laotian Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Kangpu to Present Latest Study Results of epaldeudomide (KPG-818) at the 67th ASH Annual Meeting
HEFEI, China, Nov. 18, 2025 /PRNewswire/ — Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I clinical trial results of epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida, USA. […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
